Halal for health: Scaling up halal pharmaceuticals

Halal standards govern lifestyle choices for 1.9bn Muslims around the world. But spending on halal products accounted for just 7% of global consumer spending on pharmaceuticals in 2018, compared with 17% of global spending on food. Moreover, predictions of growth have disappointed. The sector was expected to expand from US$92bn in 2018 to US$132bn in 2022, but that has now been pushed back to 2024.

Making the most of opportunity: Pharmaceutical strategy in Asia

The growth potential of Asia’s pharmaceutical markets is astounding. Indeed, pharmaceutical spending in the region is projected to rise faster than GDP. However, pharmaceutical companies face a variety of strategic challenges. Making the most of opportunity: Pharmaceutical strategy in Asia, an Economist Intelligence Unit (EIU) report sponsored by the Singapore Economic Development Board, explores how pharmaceutical companies operating in Asia can best navigate opportunities for continued expansion.

Le système de santé fondé sur la valeur en France

Value-based healthcare in France

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria

Key findings

  • In France, the level of improvement is a key determinant rather than price in deciding how innovation is valued.
  • Patient access to new drugs is highly valued and influential in how the French healthcare system is organised.
  • A lack of transparency in the way in which final prices for new drugs are negotiated curbs progress of value-based healthcare in France.

Pharma’s value proposition

The Pharma Summit 2011 brings together top pharma players to present an outlook of the pharma industry in the long term. In this video David Redfern, Chief Strategy Officer at GlaxoSmithKline, discusses how the industry must change.

On rebranding pharma

This video is one of the selected highlights from some of the experts on the subject of health and wellbeing, as part of The Big Ideas Project. Jonathan Sands, Chairman of Elmwood shared his thoughts on "rebranding pharma".

On the future for research led-pharma

In this video, John Lechleite, President and Chief Executive Officer at Eli Lilly, opens The Pharma Summit 2011 by sharing his views on the future of the industry, and poses the question: can big pharma can continue to be research-led?

The value challenge

Report Summary

The value challenge is the second in a series of four reports by the Economist Intelligence Unit, following the first report, The innovation imperative in biopharma. These reports are part of the Reinventing biopharma: Strategies for an evolving marketplace programme, sponsored by Quintiles. The Economist Intelligence Unit conducted the survey and analysis and wrote the report. The findings and views expressed in this report do not necessarily reflect the views of the sponsor.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week